Search Result

Results for "

durations

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adenosine Receptor (3) Adrenergic Receptor (8) Akt (2) Antibiotic (4) Apoptosis (7) Autophagy (10) Bacterial (19) Biochemical Assay Reagents (1) c-Fms (1) Calcium Channel (8) Cathepsin (1) Cholecystokinin Receptor (2) COX (1) Cytochrome P450 (1) Dihydroorotate Dehydrogenase (1) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (7) Dopamine Receptor (3) Dopamine Transporter (1) Drug Derivative (3) Elastase (2) Endogenous Metabolite (4) Enteropeptidase (1) Environmental Pollutants (1) ERK (1) Factor VIII (1) Fungal (1) GABA Receptor (3) GHR (1) GHSR (1) Histamine Receptor (4) Histone Demethylase (5) HMG-CoA Reductase (HMGCR) (7) HSV (1) IGF-1R (1) iGluR (3) Influenza Virus (1) Insecticide (1) Isotope-Labeled Compounds (8) JNK (1) Liposome (1) mAChR (5) mGluR (1) Mitochondrial Metabolism (2) Mitosis (1) Monoamine Oxidase (1) Motilin Receptor (2) Mps1 (1) mTOR (1) Na+/K+ ATPase (1) nAChR (1) Neurokinin Receptor (2) NF-κB (1) NO Synthase (2) NOD-like Receptor (NLR) (2) Opioid Receptor (2) Orthopoxvirus (2) p38 MAPK (2) Parasite (5) PD-1/PD-L1 (1) Phosphatase (2) PI3K (1) PINK1/Parkin (2) PKA (3) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (42) Prostaglandin Receptor (2) Reference Standards (20) Renin (1) Sigma Receptor (1) SOD (1) Sodium Channel (18) STAT (4) Thrombopoietin Receptor (1) Thymidylate Synthase (1) Thyroid Hormone Receptor (1) Tim3 (1) Topoisomerase (2) TRP Channel (1) VD/VDR (1) Virus Protease (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (61) Endocrinology (7) Infection (22) Inflammation/Immunology (21) Metabolic Disease (19) Neurological Disease (44)
Oligonucleotides:	Phospholipids (1)

142

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17504A

Rosuvastatin 20+ Cited Publications ZD 4522	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-12532

Astemizole 5+ Cited Publications R 43512	Histamine Receptor Potassium Channel	Inflammation/Immunology Endocrinology
Astemizole (R 43512), a second-generation antihistamine agent to diminish allergic symptoms with a long duration of action, is a histamine H1-receptor antagonist, with an IC₅₀ of 4 nM. Astemizole also shows potent hERG K ⁺ channel blocking activity with an IC₅₀ of 0.9 nM. Astemizole has antipruritic effects .

HY-124754

Navacaprant BTRX-335140; CYM-53093	Opioid Receptor	Neurological Disease Metabolic Disease
Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC₅₀ values of 0.8 nM, 110 nM, and 6500 nM, respectively. Navacaprant endows with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rats. Navacaprant distributes well into the CNS and can be used for the research of neuropathy .

HY-W010950

Flecainide 3 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-B0546

Procaine 2 Publications Verification	Histone Demethylase DNA/RNA Synthesis Bacterial	Neurological Disease Cancer
Procaine is a DNA-demethylating agent. Procaine acts through multiple targets and has a slow onset and a short duration of action .

HY-15891A

GW311616 hydrochloride 5+ Cited Publications GW311616A	Elastase	Inflammation/Immunology
GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (HNE) inhibitor with IC₅₀ value of 22 nM and K_i value of 0.31 nM .

HY-12533

Disopyramide 2 Publications Verification Dicorantil; SC-7031	Sodium Channel Potassium Channel	Cardiovascular Disease
Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .

HY-B0546A

Procaine hydrochloride 2 Publications Verification	Histone Demethylase DNA/RNA Synthesis Bacterial	Neurological Disease Cancer
Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action .

HY-110175

CX614 1 Publications Verification	iGluR	Neurological Disease
CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression .

HY-B1470

Azaperone R-1929	Dopamine Receptor Adrenergic Receptor	Neurological Disease
Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent .

HY-B0344

Methscopolamine bromide 1 Publications Verification (-)-Scopolamine methyl bromide; Hyoscine methyl bromide	mAChR	Neurological Disease
Methscopolamine bromide ((-)-Scopolamine methyl bromide; Hyoscine methyl bromide) is a peripherally acting muscarinic receptor (mAChR) antagonist that cannot cross the blood-brain barrier. Methscopolamine bromide blocks the muscarinic negative feedback regulation of acetylcholine release from striatal cholinergic terminals, thereby increasing acetylcholine release in the striatum of freely moving rats. Methscopolamine bromide does not induce motor excitation in freely moving rats, nor does it alter the duration of ethanol-induced loss of righting reflex in mice. Methscopolamine bromide fails to antagonize the arecoline-mediated reduction in the duration of ethanol-induced loss of righting reflex in mice .

HY-100184

DSM265 2 Publications Verification	Dihydroorotate Dehydrogenase Parasite	Infection
DSM265 is a long-duration inhibitor of P. falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC₅₀ of 8.9 nM. DSM265 can also inhibit the growth of Pf3D7 parasites with an EC₅₀ of 4.3 nM .

HY-12533A

Disopyramide phosphate 2 Publications Verification Dicorantil phosphate; SC-7031 phosphate	Potassium Channel Sodium Channel	Cardiovascular Disease
Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .

HY-B0416

Gallamine Triethiodide	mAChR Adrenergic Receptor	Neurological Disease
Gallamine Triethiodide is a blood-brain barrier-permeable skeletal muscle relaxant. Gallamine Triethiodide induces skeletal muscle paralysis by blocking acetylcholine. Gallamine Triethiodide directly stimulates intracardiac β receptors. Gallamine Triethiodide prolongs the duration of afterdischarge in the cat cerebral cortex. Gallamine Triethiodide can be used in studies related to convulsive disorders .

HY-14785

Befiradol NLX-112; F13640	5-HT Receptor	Neurological Disease
Befiradol (NLX-112) is a highly selective 5-HT₁A receptor agonist that acts on both presynaptic and postsynaptic sites. Befiradol attenuates fentanyl-induced respiratory depression in neonatal and adult rats. Befiradol reduces the duration of fentanyl-induced analgesia and sedation in adult rats. Befiradol can be used in studies related to opioid-induced respiratory depression .

HY-126569

Efrotomycin	Antibiotic Bacterial	Infection
Efrotomycin is an orally active antibiotic. Efrotomycin can be isolated from the Streptomyces Lactamdurans. Efrotomycin has insignificant effect on Salmonella typhimurium quantity, duration, shedding rate, and antimicrobial susceptibility in infected pigs .

HY-103186

MRS-1706 1 Publications Verification	Adenosine Receptor	Inflammation/Immunology
MRS-1706 is a potent and selective adenosine A_2B receptor inverse agonist. MRS-1706 has K_i values of 1.39, 112, 157, and 230 nM for human A_2B, A_2A, A₁ and A₃ receptors respectively. MRS-1706 blocks adenosine-mediated cAMP induction .

HY-112998

Efmoroctocog alfa	Factor VIII	Cardiovascular Disease
Efmoroctocog alfa is a recombinant factor VIII-Fc fusion protein (rFVIIIFc). In mice with hemophilia A, Efmoroctocog alfa provides longer-lasting protection against tail vein transection injury than conventional rFVIII products. In dogs with hemophilia A, Efmoroctocog alfa produces a longer duration of improvement in whole blood clotting time than conventional rFVIII products. Efmoroctocog alfa can be used for research on hemophilia A .

HY-W010950A

Flecainide hydrochloride 3 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide hydrochloride is an orally active antiarrhythmic agent. Flecainide hydrochloride can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide hydrochloride can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-108591

L-364,373 R-L3	Potassium Channel	Cardiovascular Disease
L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .

HY-W016414

Triethyl phosphate	Environmental Pollutants Endogenous Metabolite	Cardiovascular Disease
Triethyl phosphate is a versatile phosphate ester compound. Triethyl phosphate induces rapid and short-acting anesthesia, and exhibits hypotensive, smooth muscle relaxant, and cardiac inhibitory effects. Triethyl phosphate also modulates cholinergic toxicity; its anesthetic effect shows sex- and age-dependency in rodents, and it interacts with SKF 525-A (HY-B1311) to alter the duration of anesthesia .

HY-107691

GR 159897	Neurokinin Receptor	Neurological Disease Endocrinology Cancer
GR 159897 is a highly potent, selective, competitive, brain-penetrated non-peptide neurokinin 2 (NK₂) receptor antagonist. GR 159897 has little or no affinity for NK₁ and NK₃ receptors. GR 159897 inhibits binding of [ ³H]GR100679 to human NK₂ (hNK₂)-CHO cells and rat colon membranes with pK_is of 9.51 and 10, respectively. Antagonizes bronchoconstriction. Anxiolytic-like and anti-tumor effects .

HY-117731

UKH-1114	Sigma Receptor	Neurological Disease
UKH-1114 is a selective TMEM97 (a sigma-2 receptor) agonist with a K_i values of 1279 and 46 nM for σ1R and σ2R/TMEM97, respectively. UKH-1114 exhibits exceptional selectivity with negligible affinity for over 50 other receptors and channels. UKH-1114 effectively relieves spared nerve injury (SNI)-induced mechanical hypersensitivity with a long-lasting duration and without motor impairment. UKH-1114 can be used for neuropathic pain research .

HY-101253

AM-92016 hydrochloride 1 Publications Verification	Potassium Channel	Cardiovascular Disease
AM-92016 hydrochloride is a specific blocker of rectifier potassium current (IK). AM-92016 hydrochloride delays rectifier potassium channel (IK), repolarizes the membrane thereby restricting the duration of the nerve impulse thereby restricting the duration of the nerve impulse .

HY-32342

Falecalcitriol	VD/VDR	Metabolic Disease
Falecalcitriol(Fulstan; Hornel) is an analog of calcitriol; has a higher potency both in vivo and in vitro systems, and longer duration of action in vivo.

HY-105656

Hydrocortisone phosphate sodium Hydrocortisone 21-phosphate sodium; Cortisol 21-phosphate sodium	Phosphatase	Infection
Hydrocortisone phosphate sodium is a soft steroid with low anti-inflammatory properties and a short duration of action. Hydrocortisone phosphate sodium can be used for the research for several ocular conditions and gastric ulcers .

HY-15891

GW311616	Elastase	Inflammation/Immunology
GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (HNE) inhibitor with IC₅₀ value of 22 nM and K_i value of 0.31 nM .

HY-B0546AR

Procaine hydrochloride (Standard)	Reference Standards Histone Demethylase DNA/RNA Synthesis Bacterial	Neurological Disease Cancer
Procaine (hydrochloride) (Standard) is the analytical standard of Procaine (hydrochloride). This product is intended for research and analytical applications. Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action .

HY-126028A

(+)-Sotalol (S)-Sotalol	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
(+)-Sotalol ((S)-Sotalol) is the S-isomer of Sotalol (HY-103196). Sotalol is an orally active, non-selective β-adrenergic receptor blocker. (+)-Sotalol is an antiarrhythmic agent. (+)-Sotalol can prolong action potential duration in isolated cardiac muscle .

HY-E70012

Penicillinase	Bacterial	Infection Neurological Disease
Penicillinase is an enzyme capable of hydrolyzing penicillin. Penicillinase converts penicillin into penicilloic acid, which has no antigenicity, and destroys the antibacterial, antigenic and epileptogenic properties of penicillin. Penicillinase shortens the duration of penicillin-induced seizures and neutralizes the ability of penicillin to form epileptogenic foci. Penicillinase can be used in research related to penicillin hypersensitivity and penicillin-induced encephalopathy .

HY-W779529

Cerberin 2'-Acetylneriifolin	Na+/K+ ATPase	Cancer
Cerberin is a cardiac glycoside that has been found in C. odollam and has cytotoxic and cardiac modulatory activities. It is cytotoxic to KB and NCI H187 cancer cells (IC₅₀s=1.92 and 1.24 μg/mL).1 Cerberin inhibits Na+/K+-ATPase, increasing intracellular sodium levels and action potential duration in cardiac cells.

HY-119747

WAY-123223	Potassium Channel	Cardiovascular Disease
WAY-123223 is an orally active potassium channel (Potassium Channel) blocker. WAY-123223 prolongs the transmembrane action potential duration and cardiac refractory period of canine Purkinje fibers. In canine models, WAY-123223 increases the ventricular fibrillation threshold, restores sinus rhythm from ventricular fibrillation, and exerts antiarrhythmic effects. WAY-123223 can be used in research related to cardiovascular diseases such as arrhythmias .

HY-101764

Lintitript SR 27897	Cholecystokinin Receptor	Metabolic Disease
Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC₅₀ of 6 nM and a K_i of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC₅₀ value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin .

HY-14743B

Golotimod hydrochloride SCV 07 hydrochloride; Gamma-D-glutamyl-L-tryptophan hydrochloride	Bacterial STAT	Infection Inflammation/Immunology Cancer
Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod hydrochloride (SCV 07 hydrochloride) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod hydrochloride (SCV 07 hydrochloride) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .

HY-P4160

PDC31 THG113.31; ILGHXDYK	Prostaglandin Receptor	Endocrinology
PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca ²⁺-dependent large-conductance K ⁺-channel in human myometrial cells .

HY-17504AS

Rosuvastatin-d3 ZD 4522 d₃	Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel	Cardiovascular Disease Metabolic Disease
Rosuvastatin-d₃ (ZD 4522-d₃) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals .

HY-106718

Barucainide	Sodium Channel	Cardiovascular Disease
Barucainide is an Ib-class anti-arrhythmic agent (moderately blocking sodium channel). Barucainide exhibits concentration-dependent inhibitory effects on the maximum upstroke velocity (V_max) of Purkinje fibers and ventricular muscle in dogs. Barucainide significantly shortens the action potential duration (APD). Barucainide significantly inhibits the pacemaker activity frequency of atrial tissue in rabbits and the enhanced automaticity of Purkinje fibers under normal resting potential in response to isoproterenol. Barucainide cannot inhibit the abnormal automaticity emission frequency of canine Purkinje fibers induced by barium. Barucainide can be used for research on arrhythmias .

HY-103232

IEM-1925 bromide	mGluR	Neurological Disease
IEM-1925 bromide is an orally active glutamate receptor antagonist, increases the latent period and decreases the duration of status epilepticus in rats in a lithium-pilocarpine model of epilepsy .

HY-137986

LUF7244	Potassium Channel	Inflammation/Immunology
LUF7244 is a selective allosteric modulator of K_v11.1 channels. LUF7244 inhibits early afterdepolarizations. LUF7244 can be used for anti-arrhythmia research .

HY-B0615AS

Moricizine-d8Hydrochloride EN 313-d₈; Ethmozin-d₈; Moracizine-d₈	Isotope-Labeled Compounds	Cardiovascular Disease
Moricizine-d₈ Hydrochloride is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period .

HY-12532S

Astemizole-d3	Isotope-Labeled Compounds Histamine Receptor Potassium Channel	Inflammation/Immunology Endocrinology
Astemizole-d₃ is the deuterium labeled Astemizole. Astemizole (R 43512), a second-generation antihistamine drug to diminish allergic symptoms with a long duration of action, is a histamine H1-receptor antagonist, with an IC₅₀ of 4 nM. Astemizole also shows potent hERG K+ channel blocking activity with an IC₅₀ of 0.9 nM. Astemizole has antipruritic effects .

HY-145486

1-Arachidonoyl-sn-glycerol 3-phosphate ammonium 20:4 Lyso PA	Liposome	Neurological Disease
1-Arachidonoyl-sn-glycerol 3-phosphate ammonium (20:4 Lyso PA) is a phospholipid and an LPA derived from arachidonic acid. The concentration of 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium in plasma is significantly correlated with the age of onset of cocaine use and the duration of abstinence. 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium can be used in the research of biomarkers for cocaine use disorder (CUD) .

HY-14743

Golotimod SCV 07; Gamma-D-glutamyl-L-tryptophan	Bacterial STAT	Infection Inflammation/Immunology Cancer
Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .

HY-10419

AH23848	Thrombopoietin Receptor	Cardiovascular Disease
AH23848 (compound 6) is a competitive blocker of the thromboxane A₂ receptor and an orally effective agent, with an IC₅₀ value of 50 nM against human targets and a long duration of action.

HY-A0225B

Pirbuterol dihydrochloride (±)-Pirbuteroldihydrochloride; ARA 211dihydrochloride	Endogenous Metabolite	Cardiovascular Disease
Pirbuterol ((±)-Pirbuterol) dihydrochloride is a beta 2 adrenergic agonist with bronchodilator activity. Pirbuterol dihydrochloride is comparable in duration of action to albuterol when administered by inhalation. Pirbuterol dihydrochloride demonstrates similar beta 2 selectivity to albuterol in humans.

HY-116478

L-3373	Potassium Channel	Others
L-3373 is a voltage-dependent potassium channel inhibitor with activity that reduces the effective refractory period and the dispersion of monophasic action potential duration, while significantly reducing susceptibility to ventricular fibrillation in a cat model of left ventricular hypertrophy.

HY-B1470S

Azaperone-d4 R-1929-d₄	Isotope-Labeled Compounds Dopamine Receptor Adrenergic Receptor	Neurological Disease
Azaperone-d₄ (R-1929-d₄) is the deuterium labeled Azaperone (HY-B1470). Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent.

HY-19097

Ro-24-4736	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
Ro 24-4736 is a potent, selective, p.o.-active platelet-activating factor (PAF) antagonist with a long duration of action. Ro-24-4736 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14785A

Befiradol hydrochloride NLX-112 hydrochloride; F 13640 hydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
Befiradol (NLX-112) hydrochloride is a highly selective 5-HT₁A receptor agonist that acts on both presynaptic and postsynaptic sites. Befiradol hydrochloride attenuates fentanyl-induced respiratory depression in neonatal and adult rats. Befiradol reduces the duration of fentanyl-induced analgesia and sedation in adult rats. Befiradol hydrochloride can be used in studies related to opioid-induced respiratory depression .

HY-177311

NVP-QBE170	Sodium Channel	Metabolic Disease
NVP-QBE170 is a selective Epithelial sodium channel (ENaC) inhibitor with an IC₅₀ of 57.5 nM. NVP-QBE170 potently inhibits ENaC function in HBECs and shows a longer duration of action. NVP-QBE170 significantly attenuates ENaC activity in the airways of guinea pig models. NVP-QBE170 can be used for hyperkalaemia research .

Cat. No.	Product Name

HY-L033

Peptidomimetic Library

370 compounds

Peptidomimetics are compounds whose essential elements (pharmacophore) mimic a natural peptide or protein in 3D space and which retain the ability to interact with the biological target and produce the same biological effect. Peptidomimetics are designed to circumvent some of the problems associated with a natural peptide: e.g. stability against proteolysis (duration of activity) and poor bioavailability. Certain other properties, such as receptor selectivity or potency, often can be substantially improved. The design and synthesis of peptidomimetics are most important because of the dominant position peptide and protein-protein interactions play in molecular recognition and signaling, especially in living systems. Hence mimics have great potential in drug discovery.

MCE Peptidomimetic Library contains 370 compounds including peptoid, α-helix mimetics, β-turn/sheets mimetics, etc. This library is an indispensable tool of structure-activity relationships in drug discovery.

HY-L139

Pain-Related Compound Library

3,253 compounds

Pain is a kind of distressing feeling caused by the stimulation of tissue damage. According to the International Association for the Study of Pain (IASP), pain is defined as ”An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”.

Pain is usually classified according to its location, duration, underlying causes, and intensity. For example, acute and chronic pain, muscle pain, and nerve pain. Pain is the main symptom of most diseases, which seriously affects the quality of life and body function of patients. In the medical treatment of pain, anti-inflammatory drugs and opioid analgesic agents have traditionally been used, but the side effects are serious. In recent years, targeted drugs targeting the ERK/MAPK pathway or other targets have gradually become a research hotspot.

MCE supplies a unique collection of 3,253 compounds targeting key proteins in the pain system. MCE Pain-Related Compound Library is a useful tool for pain related research and anti-pain drug development.

Cat. No.	Product Name	Target	Research Area

HY-P3801

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) DiMe-C7	Neurokinin Receptor	Neurological Disease Metabolic Disease
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats .

HY-P4160

PDC31 THG113.31; ILGHXDYK	Prostaglandin Receptor	Endocrinology
PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca ²⁺-dependent large-conductance K ⁺-channel in human myometrial cells .

HY-14743

Golotimod SCV 07; Gamma-D-glutamyl-L-tryptophan	Bacterial STAT	Infection Inflammation/Immunology Cancer
Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .

HY-P4742A

6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA 6-FAM-AEEAC-SHK TFA	Biochemical Assay Reagents Potassium Channel	Neurological Disease
6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA (6-FAM-AEEAC-SHK TFA) is a peptide neurotoxin conjugated with a fluorescent marker. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can block voltage-gated potassium channels (kv1.1 and kv1.2) to prolong the duration of action potentials, thereby affecting the conduction of neural signals. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can be used in neuroscience research .

HY-14743R

Golotimod (Standard) SCV 07 (Standard); Gamma-D-glutamyl-L-tryptophan (Standard)	Bacterial STAT Reference Standards	Infection Inflammation/Immunology Cancer
Golotimod (Standard) is the analytical standard of Golotimod. This product is intended for research and analytical applications. Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .

Cat. No.	Product Name	Target	Research Area	Image

HY-112998

Efmoroctocog alfa	Factor VIII	Cardiovascular Disease
Efmoroctocog alfa is a recombinant factor VIII-Fc fusion protein (rFVIIIFc). In mice with hemophilia A, Efmoroctocog alfa provides longer-lasting protection against tail vein transection injury than conventional rFVIII products. In dogs with hemophilia A, Efmoroctocog alfa produces a longer duration of improvement in whole blood clotting time than conventional rFVIII products. Efmoroctocog alfa can be used for research on hemophilia A .

HY-P99913

Eflapegrastim	c-Fms	Inflammation/Immunology Cancer
Eflapegrastim is a composite protein consisting of a genetically modified granulocyte-colony stimulating factor (GCSF) molecule linked via a chemical bond to an IgG4 Fc fragment (LAPS-carrier). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .

HY-P990716

Sabestomig AZD7789	PD-1/PD-L1 Tim3	Inflammation/Immunology
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0469R

L-Lysine (Standard)	Structural Classification Microorganisms Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Virus Protease HSV
L-Lysine (Standard) is the analytical standard of L-Lysine. This product is intended for research and analytical applications. L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation . IC₅₀ & Target:L-lysine (150 mg/kg) promotes, but not initiates, bladder cancer. The administration of L-lysine to rats submitted to colovesical cystoplasty accelerates the development of transitional metaplasia of the intestinal epithelium . L-lysine (10 mg/kg) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity . In Vivo:L-lysine (10?mg/kg, p.o., pre-treated or post-treated, administration duration 15 days) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity in acute pancreatitis mice model . L-lysine (5 or 10?mg/kg, p.o., 45 days) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model .

HY-D0186R

2'-Deoxyuridine (Standard)	Structural Classification Natural Products Immune System Disorder Microorganisms Disease markers Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Thymidylate Synthase
2'-Deoxyuridine (Standard) is the analytical standard of 2'-Deoxyuridine. This product is intended for research and analytical applications. 2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) . In Vitro:The interaction between the 2-deoxyuridine and the column increases the duration of retention of 2-deoxyuridine . Gradient elution with sodium acetate buffer-ACN eluent on two ZIC-HILIC homemade columns separates 2-deoxyuridine in under 9 min . In Vivo:2'-Deoxyuridine (34.42 ng/mL, gavage, 15 min) passes the blood-brain barrier (BBB) to enter the hippocampus of mice brain . 2'-Deoxyuridine (20 mg/kg, gavage, daily for 4 weeks) improves cognition and memory loss and attenuates the damage to the hippocampus in Aβ25-35-induced mice model .

HY-N0747R

Oxypeucedanin (Standard)	Structural Classification Chrysanthemum × morifolium (Ramat.) Hemsl. Coumarins Phenylpropanoids Umbelliferae Plants Source Classification	Reference Standards Potassium Channel Apoptosis PI3K NF-κB Akt p38 MAPK ERK COX NO Synthase JNK
Oxypeucedanin (Standard) is a furanocoumarin derivative found in Angelica dahurica. Oxypeucedanin (Standard) is an orally active PI3K/AKT/NF-κB, MAPK, and ROS inhibitor. Oxypeucedanin (Standard) induces cell cycle arrest and apoptosis. Oxypeucedanin (Standard) inhibits hKv1.5 channel currents (IC₅₀: 76 nM). Oxypeucedanin (Standard) exhibits anticancer, anti-inflammatory, antioxidant and antiarrhythmic activities .

Cat. No.	Product Name	Chemical Structure

HY-17504AS1

Rosuvastatin-d6

Rosuvastatin-d₆ (ZD 4522-d₆) is deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504AS

Rosuvastatin-d3

Rosuvastatin-d₃ (ZD 4522-d₃) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals .

HY-B0615AS

Moricizine-d8Hydrochloride
Moricizine-d₈ Hydrochloride is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period .

HY-12532S

Astemizole-d3
Astemizole-d₃ is the deuterium labeled Astemizole. Astemizole (R 43512), a second-generation antihistamine drug to diminish allergic symptoms with a long duration of action, is a histamine H1-receptor antagonist, with an IC₅₀ of 4 nM. Astemizole also shows potent hERG K+ channel blocking activity with an IC₅₀ of 0.9 nM. Astemizole has antipruritic effects .

HY-B1470S

Azaperone-d4

Azaperone-d₄ (R-1929-d₄) is the deuterium labeled Azaperone (HY-B1470). Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent.

HY-17504BS2

Rosuvastatin-13C,d3 sodium

Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-B0546AS

Procaine-d4 hydrochloride
Procaine-d₄ (hydrochloride) is the deuterium labeled Procaine hydrochloride. Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action .

HY-W704876

Procaine hydrochloride-d4
Procaine hydrochloride-d₄ is the deuterium labeled Procaine hydrochloride (HY-B0546A). Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action .

Cat. No.	Product Name		Classification